Loading…
for educational and safety purposes
Ulotaront and Ralmitaront both come up in the same conversations; they overlap on Serotonin and Dopamine. Ulotaront: Ulotaront (development code SEP-363856) is an investigational antipsychotic built around a genuinely new mechanism. Ralmitaront: Ralmitaront is an investigational, selective trace amine-associated receptor 1 (TAAR1) partial agonist developed by Roche as a non-dopamine-blocking candidate antipsychotic for schizophrenia and schizoaffective disorder.
Ulotaront (development code SEP-363856) is an investigational antipsychotic built around a genuinely new mechanism. Instead of blocking dopamine D2 receptors the way every classic antipsychotic does, it is an agonist at TAAR1 (trace amine-associated receptor 1, a receptor that helps tune dopamine and other monoamine signaling) with additional serotonin 5-HT1A agonism. It has been studied mainly for schizophrenia, and because it does not directly block D2 it is hoped to avoid the movement problems and raised prolactin that dog older drugs; the evidence, though, is still early and it is not an approved medicine.
Ralmitaront is an investigational, selective trace amine-associated receptor 1 (TAAR1) partial agonist developed by Roche as a non-dopamine-blocking candidate antipsychotic for schizophrenia and schizoaffective disorder. Unlike ulotaront it has little to no activity at the serotonin 1A or dopamine D2 receptors. Its phase II trials did not demonstrate clear efficacy and its development was discontinued.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
No direct antagonism
no direct activity
Agonist
Agonist
selective partial agonist
no detectable activity
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.